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Diabetes is characterized by high blood glucose level due to either autoimmune destruction of islet β-cells or
insufficient insulin secretion or glucose non-responsive production of insulin by β-cells. It is highly desired to replace
biological functional β-cells for the treatment of diabetes. Unfortunately, β-cells proliferate with an extremely low
rate. This cellular property hinders cell-based therapy for clinical application. Many attempts have been made to
develop techniques that allow production of large quantities of clinically relevant islet β-cells in vitro. A line of studies
evidently demonstrate that β-cells can proliferate under certain circumstances, giving the hopes for generating and
expanding these cells in vitro and transplanting them to the recipient. In this review, we discuss the requirements of
microenvironmental stimuli that stimulate β-cell proliferation in cell cultures. We highlight advanced approaches for
augmentation of β-cell expansion that have recently emerged in this field. Furthermore, knowing the signaling
pathways and molecular mechanisms would enable manipulating cell proliferation and optimizing its insulin secretory
function. Thus, signaling pathways involved in the enhancement of cell proliferation are discussed as well.
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Pancreatic β-cell is considered as one of the most im-
portant cell types in the islet of Langerhans in pancreas.
It is responsible to insulin production in response to blood
glucose level. The result of either insulin deficiency or
sugar level irregulated insulin secretion is diabetes mellitus
[1]. Type I and II diabetes are two common types of
this disease. Type I diabetes (T1D) results from the auto-
immune destruction of β-cells, making the body incapable
of maintaining normoglycemia in these patients. In type II
diabetes (T2D), either the body does not produce enough
insulin due to a decrease in functional β-cell mass, or the
insulin secretion does not correlate to glucose levels in the
blood. Diabetes induces other diseases, including heart
disease and stroke, high blood pressure, kidney disease,
and blindness. The Centers for Disease Control and Pre-
vention estimated that 25.8 million people of the U.S.
population are having this disease in 2011 [2]. World
Health Organization suggested that the global number of
diabetic patients would reach 300 million and being the* Correspondence: sjin@binghamton.edu
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article, unless otherwise stated.7th leading cause of death by the year 2030 [3]. Current
treatment for T1D includes insulin supplement by either
tablet, injection, or organ transplantation [4]. However,
organ transplantation causes complications regardless the
scarcity of donors and histocompatibility matching issues
[5]. On the other hand, medical treatment for T2D is fairly
limited. Driven by the urgent need to treat patients suffer-
ing from diabetes, intensive research efforts have been
made to create biologically functional islet tissues that can
be used to replace diseased islets and to regenerate a
healthy tissue for the realization of cell-based therapy.
One of the main challenges remains in adult pancreatic
β-cell therapy is the extremely low proliferation rate which
is approximately 0.1 ~ 0.3% a day in aged adult animal and
minimum replication capacity in adult human [6]. Fortu-
nately, β-cell mass expansion can occur in early postnatal
life, pregnancy, and animal models which were genetically
modulated [7-9]. Thus, it is important to fully understand
the molecular mechanisms that allow enhancing the
pancreatic β-cell proliferation, so that cells can be cul-
tured in an environment suitable for in vitro produc-
tion. Inducers of β-cell proliferation can be classified to
extrinsic and intrinsic path. Extrinsic mitogens include:
glucose, amino acids, insulin like growth factors, prolactintral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(GLP-1), growth hormone, hepatocyte growth factor
(HGF), epidermal growth factors, transforming growth
factor (TGF), and extracellular matrix (ECM) [10-12].
The intrinsic factors include cyclins, cyclin dependent
kinases, and cyclin dependent kinas inhibitors [13]. This
review focuses on the most important extrinsic mito-
gens and signaling pathways that are involved in the
process of β-cell proliferation. The review also overviews
advanced approaches and applications in the field of islet
β-cell expansion and biological functionalization.
Native β-cells and their surroundings
Islets of Langerhans are comprised of five types of cells:
α, β, δ, ε, and PP-cells. These cells work as a micro
organ to maintain glucose homeostasis. β-cell is the
most abundant and important cell in islets, which senses
the circulating glucose level in the blood and responses
glucose level by secreting insulin accordingly [14]. β-cell
receives regulation signals from a pancreatic and non-
pancreatic environment that promote its function and
proliferation [14]. As diagramed in Figure 1, first of all, a
dense vascular network exists within the islets facilitates
efficient oxygen and insulin secretion. β-cells cross inter-
act with the endothelial cells of the capillary network
through the vascular basement membrane. β-cells secret
vascular endothelial growth factor to promote the vascu-
lar development, whereas the endothelial cells produce a
basement membrane rich with laminin to support the
insulin gene expression and secretion from β-cells and
further β-cells proliferation [15]. Second, cell-cell contacts
between β-cells, through several transmembrane recep-
tors, have a great impact on insulin gene expression andFigure 1 Summary of β-cell interaction with pancreatic
environment.glucose stimulated insulin secretion (GSIS) [16]. Third, β-
cells interact with α-cells in reciprocal secretion to main-
tain glucose homeostasis [17]. Fourth, islets are rich with
neurons from sympathetic and parasympathetic nervous
system. Interaction between β-cells and parasympathetic
neurons activates specific receptors to induce GSIS, whereas
sympathetic neurons inhibit insulin secretion as a part
of the physiological glucose homeostasis [18] (Figure 1).
Moreover, β-cells receive signals from non-pancreatic
tissues such as: liver, bone, fat, and gut, endocrine cells
of the intestine [14]. These cells secrete integrins which
bind to a G-coupled receptor on the β-cell surface to
stimulate the insulin secretion and β-cell proliferation
[19]. In the process of islet isolation all of these vascular
and nerve connections are destroyed by enzymatic di-
gestion of the pancreas and islet purification through a
density centrifugation, which could be the major cause
of malfunction of β-cell and low survival after isolation
procedures [20,21]. Motivated by the need of creating
an optimal niche for β-cell expansion, biologically func-
tional materials and signaling molecules for creating a
niche that can support cell expansion both in vitro and




Glucose is one of the important regulators in β-cell pro-
liferation, since the primary function of β-cell is to lower
blood glucose level by insulin secretion. Evidence indi-
cating the role of glucose in the β-cell proliferation has
been reported in several studies both in in vitro and
in vivo. For example, glucose is a key nutrient for cell
growth in fetal and neonatal β-cell [22], insulinoma cell
lines [23], primary islets [24], and human β-cells [25]. In
vivo glucose infusion subjected to diabetic mice and rats
result in increase in β-cell mass ultimately [26-28].
The signaling pathways which are correlated glucose
with β-cell quantity, proliferation, and apoptosis have
been extensively investigated. Several pathways revealed
to be involved are: (1) insulin autocrine effect, (2) calcium
signaling, and (3) TSC2/mTOR inhibitory signaling
pathway [29] (Figure 2). In vitro studies demonstrated
that glucose induces intracellular signaling molecules
such as phosphatidylinositol 3-kinase (PI3K), protein
kinase B (PKB), glycogen synthase kinase-3 (GSK-3), extra-
cellular signal-regulated kinase (ERK)1/2, and mammalian
target of rapamycin (mTOR), as well as insulin receptor
substrate 2 (IRS2) [30,31]. Activation of insulin receptor
leads to the activation of the Akt signaling pathway which
is considered to be one of the main pathways of β-cell
proliferation [32,33]. Moreover, this activation is down
regulated by mTOR signaling triggered by an increase
in ATP production and leads to the subsequent
Figure 2 Schematic of β-cell extrinsic mitogens and pathways regulating β-cell proliferation. Abbreviations: Cn, Calcineurin; GLP1R, GLP-1
receptor; IR, insulin receptor; PRL, prolactin; PRLR, prolactin receptor; TGFβR, transforming growth factor-β receptor.
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calcium signaling pathway has also a significant remark
through cornering, the only calcium regulated phos-
phates. Study on an investigation of the importance of
the pathway has been conducted by deleting the cal-
cineurin regulatory subunit, calcineurin b1 (Cnb1). This
study results in reduced β-cell proliferation and develop-
ing age related diabetes. The correction for this defect was
made by expressing the active nuclear factor of activated
T cell cytoplasmic 1 (NFATc1), which is a downstream
transcription factor in this pathway [34]. Moreover, activa-
tion of transcription factors cAMP response element-
binding protein (CREB) and serum response factor (SRF)
can improve β-cell growth rate through glucose/calcium
pathway [35,36].
Although the moderate glucose elevation causes an in-
crease in β-cells growth and survival, prolonged exposure
to high concentration of glucose is the main cause of β-
cell deterioration and apoptosis. This condition is called
glucotoxicity, which is caused by several of mechanismsthat are not fully understood [37,38]. A line of studies
found a number of transcriptional regulators that are sen-
sitive to the level and duration of glucose and insulin gene
expression such as MafA, NFAT [39,40], somatostatin
transcription factor-1 (STF-1), pancreatic and duodenal
homeobox 1 (Pdx-1), and the insulin control element
(ICE) [41]. It was shown that these proteins are expressed
in the presence of 0.8 mM glucose and in a prolonged
exposure to a high level of 11.1 mM glucose [37]. In
addition, MafA protein level is able to restore insulin
expression in β-cell lines along with the present of pro-
longed high glucose level [42]. High glucose concentra-
tions have also shown to inactivate AMP protein kinase
(AMPK) in the β-cell and result in impaired GSIS due
to lipid accumulation which leads to the deterioration
of β-cell function [43-45].
Another set of studies revealed that glucose toxicity may
lead to oxidative stress in organelles such as in the endo-
plasmic reticulum and mitochondria [46,47]. Increase in
oxidative stress causes a reduction binding of Pdx1 and
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defective insulin gene expression and hormone secretion
[42,48]. It is clear that the reactive oxygen species (ROS)
activate stress-induced pathways, including nuclear
factor kB (NF-κB), and c-Jun N terminal kinase (JNK)
pathways [49,50]. The subsequent JNK signaling event
leads to the inactivation of IRS-1 by its phosphorylation
on Ser307 [51]. A recent study suggested that hypoxia is
another reason causing malfunction of β-cells. Expression
of transcription factor hypoxia-inducible factor (HIF) plays
an adverse role in β-cell function [52]. Under the exposure
to a high glucose level, an alteration in the profile of β-cell
gene expression occurs, including a switch from aerobic
to anaerobic glycolysis that leads to impaired GSIS and
glucose intolerance. This was investigated through the de-
letion of the regulatory protein von Hippel-Lindau (VHL)
protein for controlling the degradation of HIF which re-
duces the cellular oxygenation level and causes hypoxia.
VHL/HIF oxygen-sensing mechanisms play a critical role
in glucose homeostasis through decreasing islet oxygen-
ation level and negatively impact β-cell function [53,54].
Furthermore, chronic hyperglycemia leads to excessive
accumulation of Ca2+ in the cytosol which is a proapopto-
tic signal that induces β-cell dysfunction and destruction
[55]. Other potent apoptosis pathways were shown to be
related to interleukin-1 β which inhibits β-cell function
and promotes Fas-triggered apoptosis in part by activating
the transcription factor NF-κB during the autoimmune
process of T1D pathogenesis [56]. However, knowledge of
the signaling pathway involved in chronic hyperglycemia
remains elusive. In particularly, the targets and the down-
stream effects of glucotoxicity have not been completely
elucidated.
Growth factors and signaling pathways
Insulin growth factor (IGF)
Expressions of insulin growth factor I (IGF-I) and II
(IGF-II) and their receptor (IGFR) were found in different
stages of pancreatic development. In fact, their expressions
act as signal for stimulating β-cell proliferation [57]. IGF-I
and IGF-II are able to enhance β-cell proliferation in rat
islets and insulinoma cell lines in vitro [58]. Interest-
ingly, the over-expression of IGF-I results in enhanced
proliferation of β-cells in transgenic mice but not the
size of islets, while the over-expression of IGF-II leads
to abnormal islet morphology with enlarged irregular
shape [59,60].
Studies also demonstrated that insulin receptor (IR) is
a stimulator for β-cell proliferation [61], where the Akt
and MAPK signaling pathways are involved [62]. Reduc-
tion in the IR by up to 80% in mouse β-cells MIN6 leaded
to reduction of growth rate, suggesting that insulin plays a
crucial role as a growth factor for this insulinoma cell line
[63]. In addition, the effect of IR substrate 1 and 2 (IRS1 &2) has also been explored as they are modulators in
the insulin/IGF signaling cascade as indicated in Figure 2.
Heterozygous mutation in IRS1/IR in mice showed
approximately 400-fold increase in circulating insulin in
parallel to severe insulin resistance with striking hyper-
plasia in the β-cell mass by 40-50-fold [64]. In contrast,
animal models deficient in IRS-2 showed abnormalities
such as low proliferation, low Pdx-1 expression, small
islet size, and increase in apoptosis [65]. Moreover, IRS-
2 over-expression is associated with glucose stimulation
in insulinoma cells. It exhibits a synergistic increment
in β-cell proliferation in glucose/IGF-1 induced manner
in vitro [66]. Another study reported that IRS-2 controls
other growth promoting mutagens such as exendin-
4, which protects β-cells from human islet amyloid
polypeptide-induced cell damage [67,68]. All of these
studies suggested that the downstream signaling of insu-
lin and IGF receptors are essential for maintaining β-cell
mass and proliferation.
Akt/PKB signaling pathway
Akt is also known as protein kinase B (PKB), is proposed
to be a crucial modulator of IRS-2-mediated signal in
β-cells (Figure 2). Deficiency in AKT2 has shown a nega-
tive impact on β-cell proliferation, which provides an evi-
dence of its importance in the signaling cascade [12]. On
the contrary, AKT2 over expression induced β-cell prolif-
eration via enhancing resistance to apoptosis and improv-
ing insulin secretion [32,33]. Some downstream targets
such as forkhead transcription factor 1 (FoxO1), glycogen
synthase kinase 3 beta (GSK3β), and the mammalian tar-
get of rapamycin (mTOR) are down-regulated by the Akt
signaling pathway and Akt functions have been described
elsewhere [69-71] (Figure 2).
Pdx-1, also known as insulin promoter factor 1 (IPF1),
has been investigated as an ultimate transcription factor of
Akt signaling, result of its phosphorylation and nuclear in-
clusion plays an important role in β-cells proliferation and
function [72]. However, it is still unknown how Pdx-1 reg-
ulates β-cell proliferation. In addition, Pdx-1 can restore
β-cells function in IRS2 knocked out mice, suggesting that
the dysregulation of Pdx-1 by IRS2 is directly related to
the development of T2D [73].
There are multiple evidences for the inversely correl-
ation between the forkhead transcription factor FoxO1
and the Pdx-1 expression. A group of studies showed
several mechanisms in which FoxO1 can antagonize Pdx-1.
FoxO1 suppression can be done through the competition
binding of forkhead box protein A2 (FoxA2) protein to
Pdx-1 promoter region and restoring Pdx-1 expression level
[74]. This was further affirmed by the expression of Pdx-1
in β-cells which contain cytoplasmic FoxO1 but not nuclear
FoxO1 [74]. A recent study also confirmed that FoxO1
inhibits β-cell neogenesis but it is required for the
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[75]. In addition, FoxO1 can lead to a nuclear exclusion
of Pdx-1 in oxidative stressed β-cell as a suppression
mechanism [76]. However, it is unclear the type of mol-
ecules that are stimulated by Pdx-1 and the mechanism
of these molecules correlating with Pdx-1 to induce β-cell
proliferation.
Prolactin, placental lactogen, and HGF
Several other growth factors, such as PRL and PL, can
also enhance β-cell proliferation rate both in vitro and
in vivo. Prolactin as well as PL are highly expressed dur-
ing pregnancy and showed to be involved in increasing
β-cells mass [77]. Injection of PRL or PL leads to higher
β-cell growth in experimental rodent [78]. Moreover,
transgenic mice over-expressing PL demonstrated a higher
β-cell growth rate associated with hyperinsulinemia [78].
In contrast, mice lacking PRL receptor reduce β-cell mass
[79]. The PRL receptor belongs to the cytokine receptor
family that is involved in the JAK/STAT signaling pathway
[80]. Thus, binding of PL and PRL molecules to PRL
receptor triggers β-cells proliferation through signaling
pathway JAK2/STAT5 (Table 1).
HGF is a mesenchyme derived growth factor involved
in proliferation, migration, and differentiation of several
types of tissues [81]. Deletion of HGF demonstrated glu-
cose intolerance and impaired GSIS. A protective effect
against apoptosis and increase of proliferation was exhib-
ited in induced dysfunction mice injected with exogenous
HGF gene [82]. HGF binds to c-Met receptor and activates
MAPK and PI3K/Akt pathways which are responsible
for β-cell proliferation [83]. Hence, HGF seems to be an
attractive potential target for therapy.
Transforming growth factor-beta (TGF-β)
Transforming growth factor (TGF) family is an important
regulator in the pancreas development and function. It
has two classes of polypeptide growth factors, TGF-α and
TGF-β. They have been implicated in the pathogenesis of
cancer, autoimmune disease, and diabetes. Several studies
have reported that the impaired TGF level can lead to theTable 1 Summary of extrinsic factors and their










HGF √ √ √
TGF √
GLP-1/GIP √ √ √ √onset of both T1D and T2D [84]. Impaired TGF-β is re-
lated to the progression of T1D in non-obese diabetic
(NOD) mice. The cause of diabetes in these mice was
autoimmune destruction of islets resulting insulin defi-
ciency [85]. An adenoviral expression vector encoding
TGF was transected to the NOD mouse islet cells. The
experimental result suggested a protection to the NOD
mouse islet cells from apoptosis and immune distraction
and delay in diabetes occurrence for 22 days compared to
the only 7 days vector transfected control [86]. Microarray
on isolated intact human islets incubated in low and/or
high glucose revealed a highly regulated TGF signaling in
the human islets. This suggests that TGF is involved in
the glucose metabolism and β-cell function as well [87,88].
Incretins
Incretins are a group of hormones that lead to an increase
in the amount of insulin released from the β-cells. GLP-1
and glucose-dependent insulinotropic polypeptide (GIP)
are the two types of incretin hormones that have been well
investigated. They are secreted from the intestine upon
glucose ingestion to stimulate insulin secretion. These two
hormones have shown to be involved in increasing β-cell
proliferation and decreasing cell apoptosis [89]. GLP-1
infusion into glucose-intolerance rats caused an increase
in the β-cell mass. Likewise, an increase in the β-cell size
and neogenesis was observed in mice treated with GLP-1.
Moreover, GLP-1 has an anti-apoptotic effect in freshly
isolated human islets [90]. Buteau and his co-workers
found that GLP-1 enhances the binding of NF-κB tran-
scription factor to two anti-apoptotic genes: inhibitor of
apoptosis protein-2 and Bcl-2, resulting in augmentation
of the expression of the anti-apoptotic proteins [7]. There-
fore, GLP-1 has been approved by the FDA for being used
for T2D treatment [91]. GIP has also shown to be a syner-
gistic mitogen inducer with glucose and a pleiotropic
growth factor for insulin-producing on INS-1 β-cells [92].
Indeed, GIP is strictly glucose dependent and it does not
show any effect during a low blood glucose level. Thus,
GIP seems to act as a blood glucose stabilizer with inverse
glucose-dependent effect on pancreatic insulin [93]. In
addition, the binding of GIP-1 to its G-protein couple re-
ceptor (GLP1R) activates downstream targets including
cAMP and PKA, intracellular calcium, and Pdx-1, leading
to Pdx-1 expression [94-96] (Figure 2). For instance,
mouse islet β-cell treated with GLP1R can activate PI3K/
Akt signal pathway and trigger a significant increase in
IRS2 [97]. On the contrary, inhibition of both c-SRC and
EGFR suppresses GLP1R-mediated PI3K pathway in INS-1
cells [98]. Recently, GLP-1 was found to be able to induce
β-cell proliferation by increasing the β-catenin nuclear con-
tent and increasing cyclic D1 expression [99]. Table 1 sum-
marizes the extrinsic factors and the downstream signaling
pathways involved in β-cell proliferation.
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Adult human islets are surrounded by an incomplete cap-
sule constituted from a single layer of fibroblasts and col-
lagen fibers. Additional matrix protein is attached to this
capsule and known as peri-insular basement membrane.
Mechanical and chemical signaling interactions between
cells and ECM are known to regulate several philological
aspects including: survival [100], proliferation [101], and
insulin secretion in islets [102]. In living tissue, cells
synthesize ECM components and deposit them to form a
niche. A niche not only affects the tissue composition and
mechanical properties, but also determines cellular fate.
As aforementioned that islet β-cell can rarely proliferate
in vitro. Thus, many attempts have been made to find out
niches required for β-cell expansion. In a recently study,
human islet cells were cultured in two ECM environ-
ments: rat ECM (804G) and bovine corneal endothelial
ECM (BCEC) in the presence of GLP-1 analogue, liraglu-
tide. It was observed that there is approximately 0.082 ±
0.034% proliferation of islet β-cells in a liraglutide treated/
BCEC culture condition. The result indicates that adult
human β-cell proliferation can occur in vitro but remains
an extremely rare event within an environment of certain
ECM and signaling molecule [103]. In another study, fully
differentiated human adult insulin-producing β-cell was
unable to proliferate in vitro regardless of whether or not
the presence of human growth hormone (hGH) and the
GLP-1 analogue liraglutide. However, hGH and GLP-1
enhanced rat β-cell proliferation [104].
Since an interaction of ECM with integrins triggers an
intracellular signaling cascade and modulates the level of
gene expressions that control cell behavior [105], effect
of integrin on β-cell proliferation has also been explored.
Studies suggested that adult human islets are expressing
special types of integrins including α3, α5, αv, α6, β1, β3Figure 3 Tissue engineering approaches for enhancing pancreatic isleand β5 [96]. Laminin-5 interacting with α6β1 integrin al-
lows rat β-cell proliferation [106]. Among ligands for the
α3β1 integrin, including fibronectin, laminin, collagen I,
and collagen IV, only collagen I and IV promote rat
INS-1 cell viability and proliferation [107]. Collagen type
I, IV, and laminin can increase survival rate of islets after
isolation procedures [108]. Nikolova and his co-workers
identified laminins as endothelial signals for promoting
insulin secretion of β-cells, and this augmentation relies
on the interaction between β1 integrin and the laminins
[109].
Tissue engineering approaches
As mentioned previously, there is a considerable interest to
understand the most important regulators and the mechan-
ism that can stimulate the pancreatic islet growth in vitro.
Tissue engineering approaches have been explored by cul-
turing cells with highly porous scaffold biomaterials to gen-
erate a three dimensional (3D) environment for improving
the islet growth and survival, as well as normal insulin
secretion (Figure 3). A line of studies demonstrated that
poly(ethylene glycol) (PEG) hydrogel scaffold can mimic
cell-cell communication microenvironment required for
insulin-secreting β-cells [110-112]. Bernard and his co-
workers developed a PEG hydrogel-based microwell cell
culture system using photolithography technique [113].
Mouse β-cells formed aggregates in PEG hydrogels and
demonstrated more than 90% cellular viability in a week
long culture. Furthermore, aggregated cells showed con-
siderable increase in insulin secretion compared with
single cell culture condition [113]. This study indicates
that cell-cell adherent junction is one of the paramount
factors required for the function of insulin-secreting β-
cell. The importance of cell-cell adherent junction for
β-cell survival and function is also evidently verified byt growth in vitro.
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collagen type I, collagen type IV, fibrinogen, fibronectin,
laminin, and vitronectin, and then used to encapsulate
β-cells. β-cell survival was significantly improved in ECM-
containing PEG hydrogels compared with in gels without
ECM over ten days. Insulin secretion was also enhanced
in cells cultured in ECM-containing hydrogels [115]. The
PEG/ECM-based scaffolds indeed contribute to the re-
establishment of the islets-ECM interaction. Hiscox group
developed a device that allows islets to be cultured in be-
tween two layers of prevascularized collagen gels. The is-
lets exhibited a higher level of viability and functionality
compared to the free islets control [116].
In another engineering approach, encapsulation of
islet cells in a 3D scaffold provides protection against
the immune cells and its antibodies. However, the diffu-
sion of low molecular weight cytokines through the
hydrogels remains to be challenge. To overcome this
issue, scaffold surface can be fabricated by coating of
PEG-hydrogel with diffusible pro-inflammatory cytokines
interleukin (IL)-1β receptor. This modification enabled
maintenance of the viability of encapsulated islet cells and
function as a glucose-stimulated insulin secretion after the
exposure of different cytokines [117]. Another strategy to
make better 3D scaffold is to inhibit TNF receptor 1 by
scaffolding PEG-diacrylate hydrogels coated with TNF
receptor 1. As a result, this modified hydrogel not only
preserved islet insulin content, but also reduced mRNA
of inducible nitric oxide synthase and IL-6 in pancreases
in experimental animals [118]. Nevertheless, impaired
oxygen diffusion within a 3D scaffold hinders the wide
use of scaffold for islet cell expansion. In particular, nor-
moxia or higher oxygen tension promotes islet β-cell
development from progenitor cells and increases β-cell
viability [119-121], as β-cells consume large amounts
of oxygen during insulin secretion [122]. Studies have
shown that islet-like cell aggregates may suffer from
hypoxia proportion to the radial distance inward lead-
ing to the cell necrosis and apoptosis as well as activa-
tion of the anaerobic metabolism [123]. This issue may
be overcome by culturing the cell aggregates in an
oxygenated system [124]. Recently, an oxygenator
made from polydimethylsiloxane (PDMS)/calcium per-
oxide enhanced the mouse β-cell proliferation and in-
sulin secretion for three weeks under hypoxic culture
conditions [120]. The oxygenating strategy is practically
promising because islet cells are usually sensitive to chem-
ical compounds such as catalyst or hydrogen peroxide.
Alternatively, mouse β-cells were cultured in suspension
in a stirred spinner flask to overcome the limitation of nu-
trient transport in conventional cell culture dish. This bio-
reactor culture facilitates cell proliferation and enlarges
sizes of β-cell aggregates with enhanced responsibility to
glucose level and incretin level [125] (Figure 3).Concluding remark
Diabetes mellitus become global epidemic diseases in re-
cent years. Especially T2D affects 5.9% of the world’s
adult population with limited medication and treatment.
This necessitates seeking of novel treatments to control
the increase rate of the diseases. Studies have revealed
that multiple mitogens or cell-ECM or cell-cell commu-
nications can induce biologically functional β-cell prolif-
eration through multitude nutrient and growth factors.
Furthermore, understanding β-cell dysfunction and failure
mechanism in the development of onset of diabetes is cru-
cial to optimize the treatment options. Due to the extremely
low proliferation capability and survival rate of the islet
β-cells after isolation procedures, finding out new cell
sources for production of clinically relevant β-cells is one
of the topics in the field of tissue engineering and regen-
erative medicine for diabetic treatment. Currently, there
are three types of cell sources in the field of regenerative
medicine to produce β-cells. They are stem cells, endo-
crine progenitors, and other mature cells in the pan-
creas and β-cell itself [126]. Significant progresses have
been achieved for each of these strategies. For example,
at first glance, human embryonic stem cell (hESC) and
its counterpart named induced pluripotent stem cell
(iPSC) are considered to be promising sources for
β-cell generation in vitro. Nevertheless, the differenti-
ation procedure is still under development and investi-
gation. Besides, the risk of teratoma formation in vitro
remains a major concern if therapeutic β-cells are pro-
duced from hESCs or iPSCs. On the other hand, it is
possible to produce β-cells from duct-lining, acinar cells
[127], or hepatocytes [128], even though it is still under
a controversial discussion [129]. It remains unclear
which approach will prove ultimately to be successful in
clinical applications. To date it remains to be a significant
challenge to generate sufficient biologically functional
β-cells to replace damaged or malfunctional β-cells. Most
likely, the future of diabetes therapies rely on the combin-
ation of fabrication of novel constructor with integration of
cell, signal molecule, and biomaterial that mimics micro-
environment that is suitable for islet β-cell development in
the body.
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